Verve Therapeutics Inc.

In News

Lilly Plans Phase II For VERVE-102 Gene-Editing Therapy After Early LDL-C Data - Citeline News & Insights

Citeline News & Insights - May 26, 2026

Lilly completes acquisition of Verve Therapeutics to advance one-time treatments for people with high cardiovascular risk - PR Newswire

PR Newswire - Jul 25, 2025

Verve Therapeutics Acquired by Eli Lilly in $1 Billion Deal - Paul, Weiss

Paul, Weiss - Jul 25, 2025

Eli Lilly acquires Verve Therapeutics in $1.3 billion deal, validating gene editing for heart disease - drugdiscoverytrends.com

drugdiscoverytrends.com - Jul 19, 2025

Verve Therapeutics Inc (VERV) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey

TradingKey - Jun 19, 2026

Verve Therapeutics, Inc. (VERV): A Bull Case Theory - Yahoo Finance

Yahoo Finance - Jul 10, 2025

Lilly buys three vaccine makers; PCSK9 base editor shows promise - BioWorld News

BioWorld News - May 26, 2026

Lilly Acquires Verve Therapeutics - Contract Pharma

Contract Pharma - Jul 28, 2025

Lilly and Verve announce expiration of Verve tender offer - PR Newswire

PR Newswire - Jul 24, 2025

Verve Therapeutics Inc (VERV) Institutional Confidence - TradingKey

TradingKey - Jun 17, 2026

Eli Lilly to Acquire Verve Therapeutics to Advance One-Time Cardiovascular Treatments - CRISPR Medicine News

CRISPR Medicine News - Jun 17, 2025

Verve Therapeutics Inc (VERV) Valuation: PE, PB & Fair Value Analysis - TradingKey

TradingKey - Jun 17, 2026

Stay Informed

Join our mailing list for the latest report releases and upcoming event notifications.

Headquartered in Boston, Mass., for over 50 years, BCC Research takes pride in being your trusted custom research and data analysts. Our mission is to provide businesses with reputable data and market research reports, so that they gain new perspectives into their field and better understand their target audience. We enable companies to access reliable information, accurate forecasts, and actionable insights, so that they may become leaders in their industry.

AI Sentiment